1. Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation.
- Author
-
Toh, H. C., Chia, W. K., Sun, L., Thng, C. H., Soe, Y., Phoon, Y. P., Yap, S. P., Lim, W. T., Tai, W. M., Hee, S. W., Tan, S. H., Leong, S. S., and Tan, E. H.
- Subjects
GRAFT versus host disease ,STEM cell transplantation ,NASOPHARYNX cancer patients ,T cells ,HOMOGRAFTS - Abstract
While nonmyeloablative peripheral blood stem cell transplantation (NST) has shown efficacy against several solid tumors, it is untested in nasopharyngeal cancer (NPC). In a phase II clinical trial, 21 patients with pretreated metastatic NPC underwent NST with sibling PBSC allografts, using CY conditioning, thymic irradiation and in vivo T-cell depletion with thymoglobulin. Stable lymphohematopoietic chimerism was achieved in most patients and prophylactic CYA was tapered at a median of day +30. Seven patients (33%) showed partial response and three (14%) achieved stable disease. Four patients were alive at 2 years and three showed prolonged disease control of 344, 525 and 550 days. With a median follow-up of 209 (4-1147) days, the median PFS was 100 days (95% confidence interval (CI), 66-128 days), and median OS was 209 days (95% CI, 128-236 days). Patients with chronic GVHD had better survival-median OS 426 days (95% CI, 194-NE days) vs 143 days (95% CI, 114-226 days) (P=0.010). Thus, NST may induce meaningful clinical responses in patients with advanced NPC. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF